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In the last 20 years, we had witnessed the emergence of the Severe acute respiratory syndrome 
(SARS) coronavirus (SARS-CoV-1), initially reported from Guangdong province, China in 2002, 
the Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) from Jeddah, Saudi 
Arabia, in 2012  and SARS-CoV-2  in December 2019  in Wuhan, Hubei province in China.  SARS-
CoV-2 had caused an ongoing global pandemic of COVID-19 (COronaVIrus Disease-2019).  These 
viruses are genetically related to the circulating seasonal human coronaviruses: 
alphacoronaviruses, NL63 and 229E, and betacoronaviruses, HKU1 and OC43.  These viruses, 
mainly NL63 or 229E, show a seroprevalence of 75% and 65 % of children by 2.5–3.5 years of 
age [1].  In addition, these seasonal coronaviruses are the etiology of respiratory infection in 22-
25 % of adults with acute respiratory illness [2,3].  The occurrence of reinfection with OC43 is at 
least partially attributed to genetic substitution in the potential cleavage site sequence of the 
spike protein [4]. 
Since the emergence of COVID-19, it has been debated and discussed whether it is possible or 
frequent to have reinfection.  It is a real possibility and it would be a major threat to the current 
measures to control the COVID-19 pandemic.   In a recent commentary, three questions were 
posed regarding reinfection with SARS-CoV-2. These questions are: how common is reinfection? 
how severe are reinfections? and what does reinfection mean for vaccines? [5].  A positive 
SARS-CoV-2 PCR after resolution of symptoms and a negative PCR may not indicate reinfection 
[6].  A true positive SARS-CoV-2 by PCR may indicates: persistence of non-viable RNA after the 
first episode, reinfection, or a relapse [7–9].  The mean time to negative SARS-CoV-2 RT-PCR 
was 24 days after symptom onset and 10% were positive at 33 days after symptom onset [10].   
3 
In a small study of 12 patients who had recurrent infection with common coronaviruses, the 
median time to reinfection was 37 weeks (4-48 weeks) and 9 of those patients had reinfection 
with OC43 and reinfection was milder [11].  In another study, 8.5% of 470 patients had 
reinfection with new or the same coronavirus was 566 and 676 days, respectively [12]. 
SARS pandemic was controlled easily and did not extend in time.  Thus, it might had not been 
possible to examine weather reinfection is a real possibility or not.  Despite, the extended 
occurrence of MERS-CoV cases since 2012, there is no clinical data on MERS reinfection.  In a 
rabbit model, reinfection was associated with enhanced pulmonary inflammation, without an 
increase in viral RNA titers [13]. 
In a rhesus macaque model of SARS-CoV-2 infection, a rechallenge with an identical SARS-CoV-2 
strain in the early recovery phase was not associated with viral dissemination, clinical 
manifestations, or histopathological changes [14].  However, the study did not look at a 
different strain and did not examine the possibility of reinfection months after initial challenge 
as the reinfection was done at day 28 of the first infection [14]. 
There are few studies showing that positive SARS-CoV-2 continues 20–22 days from onset of 
symptoms and few patients may have positive results up to 44 days [15–17]. A pregnant 
woman had positive SARS-CoV-2 PCR up to 104 days after the initial infection [18].  In one case 
series, asymptomatic patients had repeat positive RT-PCR 5- and 13-days post negative testing 
[7]. 
In one study, there were three patients who were proposed to have been reinfected [19].  The 
interval between the two infections was between 22 and 41 days and two patients had positive 
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culture at the second episode and an identified B1 (European) lineage, according to the 
Pangolin classification [19,20].  Another patient was classified to have reinfection three months 
apart. Full-length genome sequencing showed initial infection was due to a lineage B.1.1 and 
relapsing infection by a lineage A SARS-CoV-2 [21]. 
In a patient from Hong Kong, he was reported to have SARS-CoV-2 reinfection 4.5 months after 
the first infection [22].   He initially had symptomatic COVID-19 with cough, sore throat, fever 
and headache for three days and tested positive March 26, 2020.   He recovered and upon 
travel-related screening, he tested positive as he returned to Hong Kong from Spain via the 
United Kingdom on August 15, 2020.  He was asymptomatic and genetic analysis showed that 
the first infection was caused by SARS-CoV-2 strain closely related to strains from the United 
States or England, and the second infection was most closely related to strains from Switzerland 
and England with 24-nucleotide difference [22].  Sequence analysis is important in this case as it 
excluded the possibility of persistent or re-appearance of positive SARS-CoV-2 after initial 
negative test, a phenomenon that is described as intermittent SARS-CoV-2 test [23].  However, 
it is important to note that the two infections occurred 4.5 months apart and that the second 
infection was asymptomatic.  In addition, the first infection was not associated with antibodies 
whereas the second infection elicited antibodies.  An additional case of possible SARS-CoV-2 
reinfection was suspected in a case from Peru [24]. 
Two healthcare workers were reported to have asymptomatic reinfections within 3.5 months of 
the first infection [25].  In these patients, the genomes revealed 9-10 unique variant differences 
between the virus isolates from the two episode [25].  Another reinfection was reported within 
2 months in a healthcare worker [26]. One case of reinfection was thought to occur within 1 
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month [27].  In a case series and systematic review, a total of 1359 cases were presumed to 
have reactivation/reinfection [28].  This occurrence was observed in a mean days of 34.5 after 
initial COVID-19 infection and 5.6% had fever and 27.6% symptoms [28].  In 6 of 9 such cases, 
the virus was not cultured in the second infection [28].  However, these cases were more a 
persistent PCR positivity rather than a reinfection.  In a recent case from Nevada, USA, a 25-
year-old male re-tested positive for a second but distinct SARS-CoV-2 variant from the initial 
infection after two negative SARS-COV-2 tests [29].  The second infection occurred  48 days 
after the first infection and was more severe than the first infection [29].  In a patient from 
Ecuador, he had re-infection 10 weeks apart with two clades (B1.p9 GISAID and A.1.1 GISAID) 
[30]. 
An immunocompromised patient was thought to have two COVID-19 episodes fifty-nine days 
apart [31].  There were no negative samples in between the two episodes and the two strains 
differed at ten nucleotide positions [31].  This difference was thought to be enough to classify 
the second episode as a re-infection and she died 2 weeks in her second illness [31].   
The duration of SARS-specific IgG was reported in 176 patients and showed that these 
antibodies were maintained for a mean of two years with significant reduction of titers the 
third year [32].  In another study of 623 SARS patients, neutralizing IgG antibodies peaked at 20-
30 days and were sustained for >150 days [33].   A third study showed that SARS neutralizing 
antibodies appeared in the second week, peaked during week 4, and persisted in some patients 
for >200 days after onset of fever [34].  Additionally, one study showed that anti-nucleocapsid 
protein IgG antibody were positive at day 240 [35].  In a study of 56 SARS patients, neutralizing 
antibodies peaked at 4th month after the onset of disease and were undetectable in 11.8% of 
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patients at month 24 [36].  In 18 SARS patients, IgG titer peaked on day 60, and remained high 
until day 180 and decreased gradually until day 720 [37].  Anti-SARS IgG antibodies remained 
positive in 17 patients at 12 months [38]. 
What about the response to MERS-CoV infection?  There are limited studies of persistence of 
neutralizing antibodies after MERS-CoV infection.  In one study of 7 patients, neutralizing 
antibodies were detectable in 86% for at least 34 months [39].   Thus, neutralizing antibodies 
against MERS persist for a longer duration than those reported for SARS-CoV-2. 
SARS-CoV-2 antibodies decline within 8 weeks [40,41].  In addition, asymptomatic or mildly 
symptomatic patients may not develop antibodies.  In one study, 40% of asymptomatic and 
12.9% of symptomatic individuals became seronegative for IgG in the early convalescent phase 
[41]. Thus, it is presumed that individuals become vulnerable to reinfection over time.  This has 
implications for building herd immunity and effectiveness of developed vaccines.  However, it is 
important to note that antibody response is not the only immune response for protection and 
T-cell immune response is also important.  Antibodies help in neutralizing viruses and killer T-
cells help in destroying cell-infected with viruses.  While neutralizing antibodies could prevent 
an infection from occurring, T-cells deal with established infection and facilitate a robust 
antibody cell response and maturation.    
Thus, the data suggest that neutralizing antibodies in SARS and MERS patients last longer than 
those in COVID-19 patients.  As expected, the developed immunity is partial and individuals 
could get reinfected.  However, the reported cases are spare and these could not be 
generalized.  Also, it is not known if the majority of the reinfection with SARS-CoV-2 would be of 
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the same, less, or more severe.  These are important questions to be answered as we continue 
the battle against COVID-19 pandemic.  The role that memory cells play is of paramount 
importance The recent COVID-19 vaccinations such as those of Pfizer-BioNTech, Moderna, and 
Oxford AstraZeneca and the race to achieve community immunity are important to end this 
pandemic.  However, the emergence of new variants and reports of evading the immune 
response [42] are additional burdens on the global immunization efforts.  The recently emerged 
variants such as B.1.1.7 variant emerged in the United Kingdom, South Africa and Brazil. For 
example, SARS-CoV-2 B.1.1.7 variant is thought to be more transmissible than other variants. 
However, there is a concern that these variants may not be covered by immune responses in 
relation to the currently available vaccines.  Thus, reinfection with SARS-CoV-2 is possible, 
indicating that exposure to the virus may not translate to total immunity.  Given the fact that > 
111 million are infected with SARS-CoV-2, and the limited number of reported reinfections, it is 
not clear till now how significant of a problem this is likely to be.  However, it is imperative that 
all individuals, whether previously diagnosed with COVID-19 or not should take identical 
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